Mega Lifesciences Public Company Limited (MEGA-R) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.046x

Based on the latest financial reports, Mega Lifesciences Public Company Limited (MEGA-R) has a cash flow conversion efficiency ratio of 0.046x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (฿461.26 Million ≈ $14.38 Million USD) by net assets (฿9.95 Billion ≈ $310.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Mega Lifesciences Public Company Limited (MEGA-R) balance sheet quality index to measure how much of total assets are equity-financed.

Mega Lifesciences Public Company Limited - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how Mega Lifesciences Public Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Mega Lifesciences Public Company Limited earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Mega Lifesciences Public Company Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Mega Lifesciences Public Company Limited ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Shanghai Zhongzhou Special Alloy Materials Co. Ltd. SHE:300963	-0.045x
Chengdu ALD Aviation Manufacturing Corp SHE:300696	-0.006x
Sagicor Financial Company TO:SFC	0.295x
Guangdong Hongtu Technology Holdings Co Ltd SHE:002101	0.023x
MedCap AB (publ) ST:MCAP	0.034x
Aerospace Cf SHG:600855	-0.017x
Indian Metals & Ferro Alloys Limited NSE:IMFA	0.121x
Yueyang Forest & Paper Co Ltd SHG:600963	-0.032x

Annual Cash Flow Conversion Efficiency for Mega Lifesciences Public Company Limited (2011–2024)

The table below shows the annual cash flow conversion efficiency of Mega Lifesciences Public Company Limited from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see MEGA-R market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	฿9.88 Billion ≈ $307.85 Million	฿2.40 Billion ≈ $74.85 Million	0.243x	+17.40%
2023-12-31	฿9.30 Billion ≈ $289.94 Million	฿1.93 Billion ≈ $60.05 Million	0.207x	-8.96%
2022-12-31	฿8.78 Billion ≈ $273.56 Million	฿2.00 Billion ≈ $62.23 Million	0.227x	-33.05%
2021-12-31	฿8.03 Billion ≈ $250.14 Million	฿2.73 Billion ≈ $84.99 Million	0.340x	+45.53%
2020-12-31	฿6.98 Billion ≈ $217.53 Million	฿1.63 Billion ≈ $50.79 Million	0.233x	-3.57%
2019-12-31	฿6.18 Billion ≈ $192.47 Million	฿1.50 Billion ≈ $46.60 Million	0.242x	+50.75%
2018-12-31	฿5.72 Billion ≈ $178.42 Million	฿919.36 Million ≈ $28.66 Million	0.161x	-9.14%
2017-12-31	฿5.24 Billion ≈ $163.46 Million	฿927.00 Million ≈ $28.89 Million	0.177x	-34.37%
2016-12-31	฿4.68 Billion ≈ $145.87 Million	฿1.26 Billion ≈ $39.29 Million	0.269x	+91.67%
2015-12-31	฿4.33 Billion ≈ $135.11 Million	฿609.12 Million ≈ $18.99 Million	0.141x	-8.98%
2014-12-31	฿3.98 Billion ≈ $124.00 Million	฿614.22 Million ≈ $19.14 Million	0.154x	+22.40%
2013-12-31	฿3.69 Billion ≈ $115.09 Million	฿465.77 Million ≈ $14.52 Million	0.126x	-40.02%
2012-12-31	฿1.63 Billion ≈ $50.69 Million	฿342.02 Million ≈ $10.66 Million	0.210x	+3.97%
2011-12-31	฿1.32 Billion ≈ $41.09 Million	฿266.67 Million ≈ $8.31 Million	0.202x	--

About Mega Lifesciences Public Company Limited

BK:MEGA-R Thailand Drug Manufacturers - Specialty & Generic

Market Cap

$869.61 Million

฿27.90 Billion THB

Market Cap Rank

#9506 Global

#90 in Thailand

Share Price

฿32.00

Change (1 day)

+0.00%

52-Week Range

฿28.00 - ฿32.00

All Time High

฿52.19